Institute for Quality and Efficiency in Health Care

Medications

Bronchial carcinoma: Added benefit of crizotinib not proven

Since August 2016 crizotinib (trade name: Xalkori) has also been available for adults with advanced non-small cell lung cancer (NSCLC) in whom the structure of the enzyme "proto-oncogene tyrosine-protein kinase" (ROS1) is ...

page 9 from 29